Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy

Daniel M. Moreira, Boris Gershman, Laureano J. Rangel, Stephen A. Boorjian, Robert Houston Thompson, Igor Frank, Matthew K. Tollefson, Matthew T. Gettman, Robert Jeffrey Karnes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: To evaluate the incidence, predictors and oncological outcomes of pT0 prostate cancer (PCa). Methods: We conducted a retrospective analysis of 20 222 patients undergoing radical prostatectomy (RP) for PCa at the Mayo Clinic between 1987 and 2012. Disease recurrence was defined as follow-up PSA >0.4 ng/mL or biopsy-proven local recurrence. Systemic progression was defined as development of metastatic disease on imaging. Comparisons of baseline characteristics between pT0 and non-pT0 groups were carried out using chi-squared tests. Recurrence-free survival was estimated using the Kaplan–Meier method and compared using the log-rank test. Results: A total of 62 patients (0.3%) had pT0 disease according to the RP specimen. In univariable analysis, pT0 disease was significantly associated with older age (P = 0.045), lower prostate-specific antigen (PSA; P = 0.002), lower clinical stage (P < 0.001), lower biopsy Gleason score (P = 0.042), and receipt of preoperative transurethral resection, hormonal and radiation therapies (all P < 0.001). In multivariable analysis, lower PSA levels, lower Gleason score, and receipt of preoperative treatment were independently associated with pT0 (all P < 0.05). Seven patients (11%) with pT0 PCa developed disease recurrence over a median follow-up of 10.9 years. All seven patients had preoperative treatment(s) and three had recurrence with a PSA doubling time of <9 months. Compared with non-pT0 disease, pT0 disease was associated with longer recurrence-free survival (P < 0.05). Only one (1.6%) patient with pT0 disease developed systemic progression. Conclusions: pT0 stage PCa is a rare phenomenon and is associated with receipt of preoperative treatment and features of low-risk PCa. Although pT0 has a very favourable prognosis, some men, especially those who received preoperative treatment, experience a small but non-negligible risk of disease recurrence and systemic progression.

Original languageEnglish (US)
Pages (from-to)379-383
Number of pages5
JournalBJU International
Volume118
Issue number3
DOIs
StatePublished - Sep 1 2016

Fingerprint

Prostatectomy
Prostatic Neoplasms
Recurrence
Neoplasm Grading
Biopsy
Survival
Therapeutics
Prostate-Specific Antigen
Radiotherapy
Incidence

Keywords

  • disease-free survival
  • prostate cancer
  • prostatectomy
  • PSA

ASJC Scopus subject areas

  • Medicine(all)
  • Urology

Cite this

Moreira, D. M., Gershman, B., Rangel, L. J., Boorjian, S. A., Thompson, R. H., Frank, I., ... Karnes, R. J. (2016). Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy. BJU International, 118(3), 379-383. https://doi.org/10.1111/bju.13266

Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy. / Moreira, Daniel M.; Gershman, Boris; Rangel, Laureano J.; Boorjian, Stephen A.; Thompson, Robert Houston; Frank, Igor; Tollefson, Matthew K.; Gettman, Matthew T.; Karnes, Robert Jeffrey.

In: BJU International, Vol. 118, No. 3, 01.09.2016, p. 379-383.

Research output: Contribution to journalArticle

Moreira, DM, Gershman, B, Rangel, LJ, Boorjian, SA, Thompson, RH, Frank, I, Tollefson, MK, Gettman, MT & Karnes, RJ 2016, 'Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy', BJU International, vol. 118, no. 3, pp. 379-383. https://doi.org/10.1111/bju.13266
Moreira DM, Gershman B, Rangel LJ, Boorjian SA, Thompson RH, Frank I et al. Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy. BJU International. 2016 Sep 1;118(3):379-383. https://doi.org/10.1111/bju.13266
Moreira, Daniel M. ; Gershman, Boris ; Rangel, Laureano J. ; Boorjian, Stephen A. ; Thompson, Robert Houston ; Frank, Igor ; Tollefson, Matthew K. ; Gettman, Matthew T. ; Karnes, Robert Jeffrey. / Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy. In: BJU International. 2016 ; Vol. 118, No. 3. pp. 379-383.
@article{65a58645205a4c53975d9fcbe710c936,
title = "Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy",
abstract = "Objective: To evaluate the incidence, predictors and oncological outcomes of pT0 prostate cancer (PCa). Methods: We conducted a retrospective analysis of 20 222 patients undergoing radical prostatectomy (RP) for PCa at the Mayo Clinic between 1987 and 2012. Disease recurrence was defined as follow-up PSA >0.4 ng/mL or biopsy-proven local recurrence. Systemic progression was defined as development of metastatic disease on imaging. Comparisons of baseline characteristics between pT0 and non-pT0 groups were carried out using chi-squared tests. Recurrence-free survival was estimated using the Kaplan–Meier method and compared using the log-rank test. Results: A total of 62 patients (0.3{\%}) had pT0 disease according to the RP specimen. In univariable analysis, pT0 disease was significantly associated with older age (P = 0.045), lower prostate-specific antigen (PSA; P = 0.002), lower clinical stage (P < 0.001), lower biopsy Gleason score (P = 0.042), and receipt of preoperative transurethral resection, hormonal and radiation therapies (all P < 0.001). In multivariable analysis, lower PSA levels, lower Gleason score, and receipt of preoperative treatment were independently associated with pT0 (all P < 0.05). Seven patients (11{\%}) with pT0 PCa developed disease recurrence over a median follow-up of 10.9 years. All seven patients had preoperative treatment(s) and three had recurrence with a PSA doubling time of <9 months. Compared with non-pT0 disease, pT0 disease was associated with longer recurrence-free survival (P < 0.05). Only one (1.6{\%}) patient with pT0 disease developed systemic progression. Conclusions: pT0 stage PCa is a rare phenomenon and is associated with receipt of preoperative treatment and features of low-risk PCa. Although pT0 has a very favourable prognosis, some men, especially those who received preoperative treatment, experience a small but non-negligible risk of disease recurrence and systemic progression.",
keywords = "disease-free survival, prostate cancer, prostatectomy, PSA",
author = "Moreira, {Daniel M.} and Boris Gershman and Rangel, {Laureano J.} and Boorjian, {Stephen A.} and Thompson, {Robert Houston} and Igor Frank and Tollefson, {Matthew K.} and Gettman, {Matthew T.} and Karnes, {Robert Jeffrey}",
year = "2016",
month = "9",
day = "1",
doi = "10.1111/bju.13266",
language = "English (US)",
volume = "118",
pages = "379--383",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy

AU - Moreira, Daniel M.

AU - Gershman, Boris

AU - Rangel, Laureano J.

AU - Boorjian, Stephen A.

AU - Thompson, Robert Houston

AU - Frank, Igor

AU - Tollefson, Matthew K.

AU - Gettman, Matthew T.

AU - Karnes, Robert Jeffrey

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objective: To evaluate the incidence, predictors and oncological outcomes of pT0 prostate cancer (PCa). Methods: We conducted a retrospective analysis of 20 222 patients undergoing radical prostatectomy (RP) for PCa at the Mayo Clinic between 1987 and 2012. Disease recurrence was defined as follow-up PSA >0.4 ng/mL or biopsy-proven local recurrence. Systemic progression was defined as development of metastatic disease on imaging. Comparisons of baseline characteristics between pT0 and non-pT0 groups were carried out using chi-squared tests. Recurrence-free survival was estimated using the Kaplan–Meier method and compared using the log-rank test. Results: A total of 62 patients (0.3%) had pT0 disease according to the RP specimen. In univariable analysis, pT0 disease was significantly associated with older age (P = 0.045), lower prostate-specific antigen (PSA; P = 0.002), lower clinical stage (P < 0.001), lower biopsy Gleason score (P = 0.042), and receipt of preoperative transurethral resection, hormonal and radiation therapies (all P < 0.001). In multivariable analysis, lower PSA levels, lower Gleason score, and receipt of preoperative treatment were independently associated with pT0 (all P < 0.05). Seven patients (11%) with pT0 PCa developed disease recurrence over a median follow-up of 10.9 years. All seven patients had preoperative treatment(s) and three had recurrence with a PSA doubling time of <9 months. Compared with non-pT0 disease, pT0 disease was associated with longer recurrence-free survival (P < 0.05). Only one (1.6%) patient with pT0 disease developed systemic progression. Conclusions: pT0 stage PCa is a rare phenomenon and is associated with receipt of preoperative treatment and features of low-risk PCa. Although pT0 has a very favourable prognosis, some men, especially those who received preoperative treatment, experience a small but non-negligible risk of disease recurrence and systemic progression.

AB - Objective: To evaluate the incidence, predictors and oncological outcomes of pT0 prostate cancer (PCa). Methods: We conducted a retrospective analysis of 20 222 patients undergoing radical prostatectomy (RP) for PCa at the Mayo Clinic between 1987 and 2012. Disease recurrence was defined as follow-up PSA >0.4 ng/mL or biopsy-proven local recurrence. Systemic progression was defined as development of metastatic disease on imaging. Comparisons of baseline characteristics between pT0 and non-pT0 groups were carried out using chi-squared tests. Recurrence-free survival was estimated using the Kaplan–Meier method and compared using the log-rank test. Results: A total of 62 patients (0.3%) had pT0 disease according to the RP specimen. In univariable analysis, pT0 disease was significantly associated with older age (P = 0.045), lower prostate-specific antigen (PSA; P = 0.002), lower clinical stage (P < 0.001), lower biopsy Gleason score (P = 0.042), and receipt of preoperative transurethral resection, hormonal and radiation therapies (all P < 0.001). In multivariable analysis, lower PSA levels, lower Gleason score, and receipt of preoperative treatment were independently associated with pT0 (all P < 0.05). Seven patients (11%) with pT0 PCa developed disease recurrence over a median follow-up of 10.9 years. All seven patients had preoperative treatment(s) and three had recurrence with a PSA doubling time of <9 months. Compared with non-pT0 disease, pT0 disease was associated with longer recurrence-free survival (P < 0.05). Only one (1.6%) patient with pT0 disease developed systemic progression. Conclusions: pT0 stage PCa is a rare phenomenon and is associated with receipt of preoperative treatment and features of low-risk PCa. Although pT0 has a very favourable prognosis, some men, especially those who received preoperative treatment, experience a small but non-negligible risk of disease recurrence and systemic progression.

KW - disease-free survival

KW - prostate cancer

KW - prostatectomy

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=84982189642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982189642&partnerID=8YFLogxK

U2 - 10.1111/bju.13266

DO - 10.1111/bju.13266

M3 - Article

VL - 118

SP - 379

EP - 383

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 3

ER -